Table 3.
Clinical and laboratory characteristics associated with CKD development in AF patients
| Patient characteristics | AF patients without CKD development (n = 205) | AF patients with CKD development (n = 51) | HR (95% CI) | p value |
|---|---|---|---|---|
| Age, years | 61.4 ± 9.4 | 68.6 ± 6.4 | 1.09 (1.05 – 1.13) | <0.001 |
| Permanent AF | 47 (22.9) | 22 (43.1) | 2.36 (1.35 – 4.11) | 0.002 |
| Diabetes mellitus | 25 (12.2) | 15 (29.4) | 2.51 (1.37 – 4.59) | 0.003 |
| Coronary artery disease | 24 (11.7) | 13 (25.5) | 2.52 (1.34 – 4.74) | 0.004 |
| Mitral valve disease | 47 (22.9) | 24 (47.l) | 2.77 (1.59 – 4.81) | <0.001 |
| Prior stroke/TIA/systemic embolism | 13 (6.3) | 11 (21.6) | 2.78 (1.43 – 5.43) | 0.003 |
| PAD | 4 (2.0) | 4 (7.8) | 3.79 (1.36 – 8.55) | 0.003 |
| CHA2DS2-VASc score | 2.1 ± 1.1 | 3.3 ± 1.5 | 1.74 (1.47 – 2.90) | <0.001 |
| Baseline eGFR, ml/min/1.73 m2 | 83.7 ± 12.3 | 71.3 ± 8.6 | 6.73 (2.78 – 10.71)a | <0.001 |
| High-density lipoprotein cholesterol, mmol/l | 1.2 ± 0.3 | 0.8 ± 0.5 | 1.76 (1.06 – 2.92)b | 0.028 |
Variables are presented as: mean ± standard deviation or n (%).
a
HR is expressed per 30 ml/min/1.73m2 GFR decrease.
b
HR is expressed per quartile decrease in High-density lipoprotein cholesterol concentration.